Any news for pop??
Found it….sorry, just saw
Genelux Corporation Announces
First Patient Dosed in Phase 2
Trial Evaluating Systemic
Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire
- VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
- Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
- Interim readout expected mid-2025 -
WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.